Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
|
|
- Isabel Strickland
- 5 years ago
- Views:
Transcription
1 Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September 2014 NICE Diagnostics Guidance DG14 This costing statement was updated in December 2017 to reflect the updated guidance wording because the InRatio2 PT/INR monitor is no longer available. Costing statement: Point-of-care coagulometers (September 2014) 1 of 10
2 1 Introduction 1.1 The guidance on Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (NICE diagnostic technology appraisal guidance 14) has the potential to lead to cost savings for Clinical Commissioning Groups (CCGs) and NHS England through self-monitoring of coagulation status and improved management of long-term vitamin K antagonist therapy and associated adverse events for people with atrial fibrillation and heart disease. 1.2 A costing statement has been produced, rather than a costing report and costing template, because the level of uptake and the way in which the service is implemented will vary between areas. Therefore the cost impact cannot be estimated nationally, and should be assessed locally. 1.3 Depending on local arrangements the commissioner for anticoagulation services is NHS England area teams when provided in primary care or CCGs where provided through secondary care or community services. Commissioners should collaborate with providers to ensure that selfmonitoring services are appropriately funded. 2 Background 2.1 People with atrial fibrillation or heart valve disease who are treated with vitamin k antagonists usually attend anti-coagulation services in hospitals or clinics, such as for international normalised ratio (INR) testing. INR is a measure of the time it takes for blood to clot. The prescribed dose of vitamin k antagonist can then be adjusted depending on the test result. The number of visits can vary depending on the stability of the person s Costing statement: Point-of-care coagulometers (September 2014) 2 of 10
3 INR, but can be up to around 20 times per year (NICE Anticoagulation therapy Commissioning and budgeting tool). 2.2 Self-monitoring with coagulometers may reduce the frequency of visits to hospital or clinics for patients and enable them to be monitored more regularly. This may improve health outcomes by enabling the dose of therapy to be adjusted more accurately, thereby avoiding adverse events that can result from an inappropriate dose of long-term vitamin K antagonist therapy, such as stroke and major haemorrhage. 2.3 People using coagulometers for self-monitoring may either self-test or self-manage. Self-testing refers to the user doing the INR test themselves and then contacting their healthcare professional with the reading for advice on any change to the dosage of the anticoagulant that may be needed. Self-managing refers to the user doing the INR test themselves and then self-adjusting the dosage of their anticoagulant medication by following an agreed care protocol. 2.4 Expert opinion indicates that current use of coagulometers is limited and is dependent on local services. Funding for devices is often provided by patients. Costing statement: Point-of-care coagulometers (September 2014) 3 of 10
4 3 Recommendations 3.1 The guidance states that: The CoaguChek XS system is recommended for self-monitoring coagulation status in adults and children on long-term vitamin K antagonist therapy who have atrial fibrillation or heart valve disease if: - the person prefers this form of testing and - the person or their carer is both physically and cognitively able to self-monitor effectively. Patients and carers should be trained in the effective use of the CoaguChek XS system and clinicians involved in their care should regularly review their ability to self-monitor. Equipment for self-monitoring should be regularly checked using reliable quality control procedures, and by testing patients equipment against a healthcare professional s coagulometer which is checked in line with an external quality assurance scheme. Ensure accurate patient records are kept and shared appropriately. For people who may have difficulty with or who are unable to selfmonitor, such as children or people with disabilities, their carers should be considered to help with self-monitoring. 4 Patient numbers affected 4.1 Coagulometers are appropriate for people who prefer, and are physically and cognitively able to self-monitor effectively. Table 1 shows the estimated population within England who may be eligible. However of these 450,000 people the number who prefer, or are considered able to self-monitor is unknown. Table 1 Estimated eligible population for self-monitoring in England Population group Percentage Population Notes Atrial fibrillation People with atrial fibrillation 1.3% 720,000 a People with atrial fibrillation treated with vitamin K antagonists 0.6% 340,000 Costing statement: Point-of-care coagulometers (September 2014) 4 of 10
5 Heart valve disease People with heart valve disease 2.5% 1,400,000 b People with a prosthetic heart valve 0.2% 110,000 c Estimated eligible population 0.8% 450,000 d a. Atrial fibrillation affects around 800,000 people in the UK as a whole. For more information on the management of Atrial Fibrillation, see the Patient Decision Aid, Atrial Fibrillation, NICE Clinical Guideline 180, b. Nkomo V, Gardin J, Skelton T et al. (2006) Comment in Lancet Sep 16; 368(9540):969-7 c. While the recommendations relate to people who have heart valve disease, those with a prosthetic heart valve are more likely to be treated with vitamin k antagonists and therefore affected by the guidance. As a result this group has been used in the estimated potentially eligible population. d. Additional information on the population affected by the recommendations is available in the guidance 4.2 The number of people who self-monitor may be determined by how many training slots are available and the number of devices that are commissioned. The proportion of people who are trained to self-monitor and then discontinue should be estimated locally. Costing statement: Point-of-care coagulometers (September 2014) 5 of 10
6 5 Resource impact Potential costs 5.1 Self-monitoring incurs additional costs for purchasing coagulometers and training people to use them, as well as ongoing costs for consumables such as testing strips and lancets. A full breakdown of the estimated costs is included in appendix A. 5.2 A summary of the initial investment and annual costs is shown in table 2 below. The costs depend on whether the service is being administered in primary or secondary care. Table 2 Annual costs for self-monitoring with the CoaguChek XS in primary or secondary care Self-testing Self-management Setting Initial investment Annual administration cost Primary care Secondary care Primary care Secondary care The list price (at the time of publication) of CoaguChek XS is 299. The year 1 costs shown in table 2 include initial purchase of the device, along with training and management costs. The device may have to be replaced such as due to loss or damage. 5.4 Self-testing typically involves the person being phoned by the clinic administering the service to check their test results and recommend dosage changes. This means that costs can be incurred where there are additional staffing requirements, and for telephone calls. Increasingly however, IT systems are being used to automate this system, potentially Costing statement: Point-of-care coagulometers (September 2014) 6 of 10
7 reducing such costs. The impact of implementing such a service should be assessed locally. 5.5 The cost of the device and consumables could affect CCGs where the service is provided through secondary care or community services, and/or NHS England where the service is provided in primary care. Potential savings and benefits 5.6 Self-monitoring allows greater frequency of INR monitoring, and so more appropriate dosage of oral anticoagulants. This can reduce rates of adverse events such as stroke or major haemorrhages, and therefore future treatment costs. A detailed breakdown of the treatment costs potentially avoided are included in appendix B; a summary is provided below: Major bleed (non-cranial): 1120 Systemic embolism: 1050 Minor stroke: 5600 initial treatment cost; 310 per quarter on an ongoing basis Major stroke: 8000 initial treatment cost; 4000 per quarter on an ongoing basis 5.7 As the costs of treating adverse events are considerably higher than those of self-monitoring, avoiding a small number of high-cost adverse events has the potential to make the initial investment cost-saving. 5.8 The adverse events avoided through anti-coagulation services are predominantly treated through secondary care. As a result, savings are expected to affect CCGs. 5.9 Where self-monitoring leads to decreased demand for services such as anti-coagulation clinics there may be savings for both CCGs and NHS England. The annual cost of anti-coagulation monitoring within a primary or secondary care setting has been estimated to be approximately 250 Costing statement: Point-of-care coagulometers (September 2014) 7 of 10
8 per person (Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation, NICE Guidance TA249 increased in line with CPI inflation). These potential savings should be considered locally The guidance includes an assumption that some devices can be reused when a person who is self-monitoring discontinues, which may lead to efficiency savings in the administration of the self-monitoring service Additional benefits of coagulometer services for patients include not having to attend anticoagulation clinics on a regular basis and the avoidance of costs of the coagulometer device which may currently be incurred by the patient. 6 Conclusion 6.1 Self-monitoring through use of the CoaguChek XS coagulometer has the potential to be cost-saving for CCGs as the increased frequency of INR monitoring may improve health outcomes by enabling the dose of therapy to be adjusted more accurately, thereby avoiding adverse events that can result from an inappropriate dose of long-term vitamin K antagonist therapy, such as stroke and major haemorrhage. 6.2 The use of self-monitoring may also result in a decreased demand for INR monitoring at anticoagulation clinics which may lead to savings in these services for CCGs and NHS England. 6.3 Additional monitoring costs can be more than offset by savings because of the avoidance of a small number of adverse events. 6.4 Rather than the purchase of the device being funded by patients, the initial investment in training, the device and the consumables may be provided by CCGs or NHS England area teams, depending on how the service is commissioned. Commissioners should collaborate with providers to ensure that self-monitoring services are appropriately funded. Costing statement: Point-of-care coagulometers (September 2014) 8 of 10
9 Appendix A Costs of self-monitoring Self-monitoring costs Primary care Secondary care Self-testing CoaguChek XS CoaguChek XS Year 1 cost Device list price Training Initial costs Total year 1 costs Annual recurrent costs Test strips and lancets Quality control tests Phone calls (nurse time) Annual recurrent costs Self-management Year 1 cost Device list price Training Initial costs Total year 1 costs Annual recurrent costs Test strips and lancets Quality control tests Annual recurrent costs Device list prices were provided by the manufacturers. Actual cost may vary. 2. Existing literature and expert opinion suggests self-testing would require two hours, and self-management four hours of one-to-one training. Training time was costed using hourly rates for patient contact time - 45 per hour for practice nurses in primary care, and 85 per hour for hospital clinic nurses (Unit costs of health and social care, 2013). Where staff time is available to provide this service along with current responsibilities, there may be no additional cost. 3. Unit costs of test strips were provided by the manufacturer, with test strips costing Lancets were approximately It was assumed that all self-monitoring would include around 35 tests per year. 4. It was assumed that twice annually coagulometers would be checked against an externally validated one, with each visit requiring 15 minutes of face-to-face contact time (see costs on footnote 2). Where staff time is available to provide this service along with current responsibilities, there may be no additional cost. Each test also requires a testing strip and a lancet. 5. It was assumed that where additional staff time was required for people who are selftesting to call in each test result would be 5 minutes of band 5 nurse time for each of the 35 tests (see costs on footnote 2). Where staff time is already available to provide this service along with their current responsibilities, there may be no additional cost. Costing statement: Point-of-care coagulometers (September 2014) 9 of 10
10 Appendix B Adverse event treatment costs Adverse events Type of treatment Cost ( ) Source Description Transient events Minor bleed Acute treatment 118 VB07Z category 2 investigation with category 2 treatment Major bleed Cost of a gastro-intestinal bleeding treatment episode. Weighted (nonintracranial) Acute treatment 1,122 PbR Costs 2014/15 average of codes: FZ38D, FZ38E, FZ38F, FZ43A, FZ43B, FZ43C Systemic Cost of non-surgical peripheral vascular disease. Weighted average of Acute treatment 1,046 embolism codes: QZ17A, QZ17B, QZ17C Permanent events Acute treatment 3,582 PbR Costs 2014/15 AA22A and AA22B: non-transient stroke or cerebrovascular accident, nervous system infections or encephalopathy (weighted average) Minor stroke Follow-on care costs per quarter 309 Wardlaw 2006; NICE Clinical Guideline CG92 Increased by rate of inflation (CPI) to 2014 Major stroke Acute treatment / National schedule of 7,964 rehabilitation reference costs 2014/15: Per excess bed day 204 non elective inpatient Follow-on care costs per quarter 3,984 Wardlaw 2006; NICE Clinical Guideline CG92 AA22A and AA22B: non-transient stroke or cerebrovascular accident, nervous system infections or encephalopathy (weighted average); rehabilitation at 313 per day for 14 days Increased by rate of inflation (CPI) to 2014 Intracranial bleed Acute treatment / rehabilitation Follow-on care (costs per quarter) 5,856 PbR Costs 2014/15 2,674 Nice Clinical Guideline CG92 AA23A and AA23B - haemorrhagic cerebrovascular disorders with CC and haemorrhagic cerebrovascular disorders without CC (weighted average); rehabilitation at 313 per day for 14 days Increased by rate of inflation (CPI) to 2014 Costing statement: Point-of-care coagulometers (September 2014) 10 of 10
2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
THEME: EFFECTIVENESS OF INRatio2 PT/INR MONITOR Comment Name and number organisation 1. Consultee 10: Alere Section number Section1 Comment We do not agree that the INRatio2 PT/ INR monitor is only recommended
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationPutting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)
Putting NICE guidance into practice Resource impact report: Hearing loss in adults: assessment and management (NG98) Published: June 2018 Summary This report focuses on the recommendation from NICE s guideline
More informationDiagnostics Assessment Programme. Final scope
Diagnostics Assessment Programme Self-monitoring coagulometers (CoaguChek XS system, INRatio2 PT/INR monitor and ProTime Microcoagulation system), for selftesting or self-managing coagulation status in
More informationDiagnostics guidance Published: 24 September 2014 nice.org.uk/guidance/dg14
Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) Diagnostics guidance Published: 24 September 2014 nice.org.uk/guidance/dg14
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationCosting statement: chronic idiopathic constipation - Lubiprostone
Putting NICE guidance into practice Costing statement: chronic idiopathic constipation - Lubiprostone Implementing the NICE guidance on Lubiprostone for treating chronic idiopathic constipation (TA318)
More informationAHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017 Introduction This business case template has been created so that
More informationPutting NICE guidance into practice. Resource impact report: Post-traumatic stress disorder (NG116)
Putting NICE guidance into practice Resource impact report: Post-traumatic stress disorder (NG116) Published: December 2018 Summary This report focuses on the recommendations from the NICE guideline on
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial Response
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTechnology appraisal guidance Published: 23 May 2012 nice.org.uk/guidance/ta256
Rivaroxaban for the prevention ention of stroke and systemic embolism in people with atrial fibrillation Technology appraisal guidance Published: 23 May 2012 nice.org.uk/guidance/ta256 NICE 2018. All rights
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationPutting NICE guidance into practice. Resource impact report: ifuse for treating chronic sacroiliac joint pain (MTG39)
Putting NICE guidance into practice Resource impact report: ifuse for treating chronic sacroiliac joint pain (MTG39) Published: October 2018 Summary NICE has recommended ifuse for treating chronic sacroiliac
More informationPutting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Putting NICE guidance into practice Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Published: November 2017 Summary This report focuses on the recommendations
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationTechnology appraisal guidance Published: 25 July 2012 nice.org.uk/guidance/ta261
Rivaroxaban for the treatment of deep vein thrombosis and prevention ention of recurrent deep vein thrombosis and pulmonary embolism Technology appraisal guidance Published: 25 July 2012 nice.org.uk/guidance/ta261
More informationTechnology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275
Apixaban for preventing enting stroke and systemic embolism in people with nonvalvular atrial fibrillation Technology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275 NICE 2018.
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationTechnology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249
Dabigatran an etexilate for the preventionention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249 NICE 2012. All
More informationGuideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Stroke and transient ischaemic attack in over s: diagnosis and initial management (update) 0 0 This will update the NICE on stroke and
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationThat the Single Commissioning Board supports the project outlined in this report and proceeds as described.
Report to: SINGLE COMMISSIONING BOARD Date: 26 September 2017 Officer of Single Commissioning Board Subject: Report Summary: Recommendations: Jessica Williams Interim Director of Commissioning ATRIAL FIBRILLATION
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationTechnology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327
Dabigatran an etexilate for the treatment and secondary prevention ention of deep vein thrombosis and/or pulmonary embolism Technology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationRhona Maclean
An early evaluation of the impact of the North Trent policy regarding the use of Non-Vitamin K antagonists for SPAF in a secondary care anticoagulation clinic Rhona Maclean Rhona.maclean@sth.nhs.uk Risk
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More information18/09/2012. Dr. Khalid Khan Consultant Cardiologist BCUHB. Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham
Dr. Khalid Khan Consultant Cardiologist BCUHB Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham 1 NICE vs. Local Guidance NICE says no We say no NICE says yes We say no NOACs
More informationSpecialist Fertility Treatment Local Criteria
Meeting: Date: June 2014 Subject: Report of: Summary: Central Bedfordshire Council Overview and Scrutiny Committee Specialist Fertility Treatment Local Criteria Dr Diane Bell and Angelina Florio This report
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationAdditional cost-effectiveness analysis scenarios prepared for the Diagnostic Advisory Committee. Produced by the Aberdeen HTA group
The clinical and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving
More informationTechnology appraisal guidance Published: 23 September 2015 nice.org.uk/guidance/ta355
Edoxaban for preventing enting stroke and systemic embolism in people with non- valvular atrial fibrillation Technology appraisal guidance Published: 23 September 2015 nice.org.uk/guidance/ta355 NICE 2015.
More informationNational Diabetes Treatment and Care Programme
National Diabetes Treatment and Care Programme Introduction to and supporting documentation for VALUE BASED TRANSFORMATION FUNDING SITE SELECTION December 2016 1 Introduction and Contents The Planning
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
More informationA. Service Specification
A. Service Specification Service Specification No: 1767 Service Adult Highly Specialist Pain Management Services Commissioner Lead For local completion Lead For local completion 1. Scope 1.1 Prescribed
More informationRadiofrequency ablation for atrial fibrillation in association with other cardiac surgery
Issue date: May 2005 Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery Understanding NICE guidance information for people considering the procedure, and for the
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationAtrial Fibrillation and Anticoagulants
Atrial Fibrillation and Anticoagulants A guide to your diagnosis and treatment Information for patients, relatives and carers For more information, please contact: York Anticoagulant Clinic Tel: 01904
More informationNHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationFreeStyle Libre for glucose monitoring: Interim Position Statement for GPs & Patient FAQ
North Central London Joint Formulary Committee FreeStyle Libre for glucose monitoring: Interim Position Statement for GPs & Patient FAQ GPs should not prescribe FreeStyle Libre sensors on the NHS until
More informationAgenda Item No. 8a SERVICE SPECIFICATION. 1. Introduction:
SERVICE SPECIFICATION Agenda Item No. 8a Service Specification No. Service Atrial Fibrillation Audit patient reviews Commissioner Lead Caroline Davidson Period 1 st September to 31 st March 2017 Date of
More informationWarfarin Guidelines for Primary Care
Warfarin Guidelines for Primary Care Produced by NECS Medicines Optimisation Team Date Produced: March 2014 Review Date: March 2016 Date Approved by: South Tees CCG March 2014 Version: 1.1 This guideline
More informationNICE Quality Standards and commissioning dementia care
NICE Quality Standards and commissioning dementia care 1 What is NICE? World leader in producing guidance and setting standards for high quality care and for promoting healthy living From April 2013 a
More informationEconomic Impact Evaluation Case Study: AliveCor Kardia Mobile
NHS Innovation Accelerator Economic Impact Evaluation Case Study: AliveCor Kardia Mobile 1. BACKGROUND The AliveCor Kardia Mobile ECG (Kardia Mobile) is a portable single-channel cardiac event recorder
More informationNHS Rotherham Clinical Commissioning Group
NHS Rotherham Clinical Commissioning Group Operational Executive: 2 nd November 2015 Governing Body: 4 th November 2015 Review of Stroke Care Pathway GP Lead: Dr Phil Birks Lead Executive: Keely Firth
More informationTechnology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264
Alteplase for treating acute ischaemic stroke Technology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationGOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4
GOVERNING BODY MEETING in Public 22 February 2017 Paper Title Purpose of paper Redesign of Services for Frail Older People in Eastern Cheshire To seek approval from Governing Body for the redesign of services
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation Consensus Statement ~ October 2011 Contents 1 About 3 2 Introduction 5 3 Development of the consensus
More informationPutting NICE guidance into practice
Putting NICE guidance into practice Costing statement Implementing the NICE guidance on Oral health: approaches for local authorities and their partners to improve the oral health of their communities
More informationPatients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures
This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Mandatory headings 1 4: mandatory but detail for local determination and agreement Optional headings 5-7: optional to use, detail for local determination
More informationDRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
More informationPoint of Care Testing for INR using CoaguChek XS Plus
Point of Care Testing, Pathology Page 1 of 18 Point of Care Testing for INR using CoaguChek XS Plus EDITION No 1.4 DATE OF ISSUE Feb 2014 REVIEW INTERVAL AUTHOR LOCATION OF COPIES 3 YEARS D O Neill 1.
More information2. Quality and Outcomes Framework: new NICE recommendations
Proposed Changes to the GMS Contract 2013/14 1. GP pay and expenses uplift It is proposed GP pay and expenses is uplifted by 1.5%. This increased investment will allow for an average pay increase of up
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationCryoablation for atrial fibrillation in association with other cardiac surgery. Issue date: May 2005
Issue date: May 2005 Cryoablation for atrial fibrillation in association with other cardiac surgery Understanding NICE guidance information for people considering the procedure, and for the public Information
More informationPlanning for delivery in 15/16 for the Dementia and IAPT Ambitions
Planning for delivery in 15/16 for the Dementia and IAPT Ambitions 24th March 2015 Welcome to the planning WebEx: Dementia and IAPT delivery in 2015/16 Please ensure you are logged into the audio via a
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationResource impact report: Eating disorders: recognition and treatment (NG69)
Resource impact report: Eating disorders: recognition and treatment (NG69) Published: May 2017 Summary This report looks at the resource impact of implementing NICE s guideline on eating disorders: recognition
More informationAudit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)
Audit support for continuous subcutaneous insulin (review of technology appraisal guidance 57) Issue date: 2008 Audit support Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationAnalysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group
Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb Tro Kalayjian Chief Medical Analyst Chimera Research Group Prevalence of AFib in the US is expected to increase upwards of
More informationCosting tool: Osteoarthritis Implementing the NICE guideline on osteoarthritis (CG177)
Putting NICE guidance into practice Costing tool: Osteoarthritis Implementing the NICE guideline on osteoarthritis (CG177) Published: February 2014 This costing report accompanies the clinical guideline
More informationEdoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
More informationThis booklet has been published by CREST (the Clinical Resource Efficiency Support Team).
This booklet has been published by CREST (the Clinical Resource Efficiency Support Team). CREST is a small committee of health care professionals established under the auspices of the Central Medical Advisory
More informationQOF indicator area: Chronic Obstructive Pulmonary disease (COPD)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Chronic Obstructive Pulmonary Disease QOF indicator area:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationTechnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta354
Edoxaban for treating and for preventingenting deep vein thrombosis and pulmonary embolism Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta354 NICE 2017. All rights reserved.
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS. Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically
More informationOn warfarin? Free up your life with CoaguChek XS. CoaguChek XS Information Pack
On warfarin? Free up your life with CoaguChek XS CoaguChek XS Information Pack Self-monitoring has given me freedom from being tied to regular appointments to have my blood checked. I am free to travel
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationA2.1: Main model assumptions
Appendix 2: Main assumptions and structure of the economic model We assumed that before the introduction of DOACs standard of care for AF patients was warfarin. For patients on warfarin as first-line treatment,
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationLow back pain and sciatica in over 16s NICE quality standard
March 2017 Low back pain and sciatica in over 16s NICE quality standard Draft for consultation This quality standard covers the assessment and management of non-specific low back pain and sciatica in young
More informationPutting NICE guidance into practice
Putting NICE guidance into practice Resource impact report: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after
More informationBOTULINUM TOXIN (BOTOX) POLICY HYPERHIDROSIS - PRIOR APPROVAL
BOTULINUM TOXIN (BOTOX) POLICY HYPERHIDROSIS - PRIOR APPROVAL Version: Ratified by: 1617.v2c SCCG COG Date Ratified: 11 May 2016 Name of Originator/Author: Name of Responsible Committee/Individual: IFR
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationFINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY
FINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY What is your view of the effects of the demographic change and an ageing population on the
More informationSouth East Coast Operational Delivery Network. Critical Care Rehabilitation
South East Coast Operational Delivery Networks Hosted by Medway Foundation Trust South East Coast Operational Delivery Network Background Critical Care Rehabilitation The optimisation of recovery from
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More information